# Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial

> **NCT03753919** · PHASE2 · TERMINATED · sponsor: **Grupo Espanol de Tumores Neuroendocrinos** · enrollment: 79 (actual)

## Conditions studied

- Metastatic Thyroid Papillary Carcinoma
- Metastatic Thyroid Follicular Carcinoma
- Metastatic Thyroid Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab

## Key facts

- **NCT ID:** NCT03753919
- **Lead sponsor:** Grupo Espanol de Tumores Neuroendocrinos
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-02
- **Primary completion:** 2024-11-08
- **Final completion:** 2024-11-08
- **Target enrollment:** 79 (ACTUAL)
- **Why stopped:** In compliance with current legislation applicable to Clinical Trials, following the instructions of the Spanish Agency for Medicines and Health Products.
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03753919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03753919, "Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03753919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*